Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track record of the firm behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 110,000 investors, many of whom demonstrate better investing insight than published analysts do.
Enough top-performing CAPS investors have recently turned bullish on ImClone
With ImClone's cancer drug Erbitux finding new uses in treating various forms of cancer, investors see more potential for the biotech firm to significantly expand revenues. ImClone recently detailed the effectiveness of its drug in treating non-small cell lung cancer (NSCLC) patients, and the results should be good enough to enable partner Bristol-Myers Squibb
But while the lead lung cancer drug -- Avastin from Genetech -- provides longer life spans, it is not recommended for patients with blood disorders, or those taking blood thinning agents. This leaves a big opportunity for ImClone's drug to be the treatment of choice for these patients. CAPS investors are increasingly seeing more potential at ImClone, with more than 86% of the investors rating the company now expecting it to outperform the market.
To see what the very best CAPS analysts are saying now about Imclone -- as well as other winning stocks they're picking -- head on over to CAPS and have a look. The community research and resources in CAPS are totally free, unlike analyst opinions reserved for paying clients.